GlassScriptPhysician profile
Melanie Green
NPI 1093026130
$3,452.18
in general payments reported to CMS, 2019-2025
27 companies · $1,279 in 2025
The $1,279 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $78.03 · 2021: $373 · 2022: $718 · 2023: $459 · 2024: $354 · 2025: $1,279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,074 · Education: $18.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,074.26 |
| Education | $18.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,197.12 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $387.19 | 2019-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $385.54 | 2021-2025 | Xifaxan, Trulance |
| Celgene Corporation | $188.03 | 2021-2023 | Zeposia |
| Janssen Biotech, INC. | $153.60 | 2021-2025 | Tremfya, Simponi, Stelara |
| Ironwood Pharmaceuticals, INC | $145.81 | 2020-2023 | Linzess |
| Pfizer INC. | $136.16 | 2021-2025 | |
| Lilly USA, LLC | $134.27 | 2023-2025 | Omvoh |
| Novo Nordisk INC | $119.04 | 2025 | Wegovy |
| Redhill Biopharma INC. | $94.95 | 2020-2021 | |
| Madrigal Pharmaceuticals | $73.81 | 2025 | Rezdiffra |
| Qol Medical, LLC | $65.22 | 2021-2025 | Sucraid |
| Celltrion USA INC. | $59.54 | 2023-2025 | Vegzelma, Yuflyma |
| Daiichi Sankyo INC. | $43.77 | 2021-2022 | |
| Gilead Sciences, INC. | $41.49 | 2021-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $40.38 | 2024-2025 | |
| Medtronic, INC. | $25.35 | 2025 | Transorb |
| Ardelyx, INC. | $22.65 | 2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $21.85 | 2024 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $19.17 | 2025 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $15.79 | 2021 | |
| Intercept Pharmaceuticals, INC. | $15.25 | 2023 | Ocaliva |
| Braintree Laboratories, INC. | $15.11 | 2025 | Suflave, Sutab |
| Evoke Pharma, INC. | $14.37 | 2025 | |
| Amgen INC. | $13.06 | 2022 | |
| Alfasigma USA, INC. | $11.99 | 2021 | |
| Organon LLC | $11.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.